ECT GmbH

Germany
Germany
SEARCH FILTERS
Time filter
Source Type

Citizens Commission on Human Rights to Participate at Father’s Day Event The Citizens Commission on Human Rights of Nashville (CCHR Nashville) has been hard at work to spread information to parents on their basic rights so they can help their children. Nashville, TN, May 27, 2017 --( CCHR has long been an advocate for human rights, especially as relates to patients’ rights in the field of mental health. Per the international CCHR website, cchr.org, “CCHR has long fought to restore basic inalienable human rights to the field of mental health, including, but not limited to, full informed consent regarding the medical legitimacy of psychiatric diagnosis, the risks of psychiatric treatments, the right to all available medical alternatives and the right to refuse any treatment considered harmful.” Rev. Brian Fesler, who serves on the board of CCHR Nashville, said, “CCHR volunteers are getting the word out, but there is so much work to be done. People are getting hurt every day at the hands of psychiatrists.” CCHR is a non-profit, non-political, non-religious mental health watchdog. Its mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. CCHR receives reports about abuses in the field of mental health and is especially interested in situations where persons experienced abuse or damage due to a false diagnosis or unwanted and harmful psychiatric treatments, such as psychiatric drugs, electroshock (ECT) and electronic or magnetic brain stimulation (TMS). CCHR is often able to assist with filing complaints, and can work with a person’s attorney to further investigate the case. To contact CCHR Nashville for more information, visit cchrnashville.org. Nashville, TN, May 27, 2017 --( PR.com )-- The Citizens Commission on Human Rights Nashville Chapter (CCHR Nashville) is working to educate parents on their basic rights as they relate to their children’s mental health and well-being. To do this, volunteers have been to several recent events and informational fairs, and now are preparing to participate in Father’s Day celebrations in Nashville.CCHR has long been an advocate for human rights, especially as relates to patients’ rights in the field of mental health. Per the international CCHR website, cchr.org, “CCHR has long fought to restore basic inalienable human rights to the field of mental health, including, but not limited to, full informed consent regarding the medical legitimacy of psychiatric diagnosis, the risks of psychiatric treatments, the right to all available medical alternatives and the right to refuse any treatment considered harmful.”Rev. Brian Fesler, who serves on the board of CCHR Nashville, said, “CCHR volunteers are getting the word out, but there is so much work to be done. People are getting hurt every day at the hands of psychiatrists.”CCHR is a non-profit, non-political, non-religious mental health watchdog. Its mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. CCHR receives reports about abuses in the field of mental health and is especially interested in situations where persons experienced abuse or damage due to a false diagnosis or unwanted and harmful psychiatric treatments, such as psychiatric drugs, electroshock (ECT) and electronic or magnetic brain stimulation (TMS). CCHR is often able to assist with filing complaints, and can work with a person’s attorney to further investigate the case. To contact CCHR Nashville for more information, visit cchrnashville.org.


News Article | May 24, 2017
Site: co.newswire.com

At the American Psychiatric Association in San Diego, California, human rights group demands an end to ECT (electroconvulsive treatment) and a nationwide ban against using the so-called treatment on children. In a rally organized by the mental health watchdog group Citizens Commission on Human Rights (CCHR), marchers descended on the American Psychiatric Association’s (APA) Annual Meeting at the San Diego Convention Center to oppose the APA’s support of electroshock treatment, also known as ECT. With the participation of other groups, San Diego psychologist Lt. Col. (Ret.) Bart Billings and Texas psychologist Dr. John Breeding told the rally that electroshock, which is administered to 100,000 Americans every year, should be banned. California was the first state to ban electroshock use on children in 1976, which CCHR was instrumental in helping to obtain. The group says the law set a global precedent for patients’ rights and they want California to lead the way again by prohibiting all use of electroshock, a practice that sends up to 460 volts of electricity through the brain. Following the rally, Billings and Breeding opened the CCHR Psychiatry: An Industry of Death exhibit that documents the history of psychiatry and its use of electroshock and other destructive practices. The exhibit is open daily until May 27 in San Diego at 1047 J Street. Between 2011 and 2015, the number of people receiving ECT in California declined from 5,766 to 1,936 — a 66 percent decrease. CCHR says the prohibition of ECT for those age 12 years and younger in California didn’t go far enough. At least eight adolescents in the state age 13–17 were subjected to ECT in 2015. Psychiatrists admit they don’t know how ECT works and that it doesn’t cure, but persist in using the practice that rakes in $2.5 billion a year. At the opening of the exhibit, Dr. Billings, author of Invisible Scars: How to Treat Combat Stress and PTSD without Medication, said: “I feel any treatment that destroys healthy brain cells, which ECT does, should be seen as criminal abuse.” He is concerned that members of the military and veterans are being given ECT, especially when some may already be suffering from brain injuries. Statistics recently obtained from Tricare and Veteran Affairs show 777 active members of the military or their family members and 1,006 veterans received electroshock in 2015. Dr. John Breeding, Ph.D., an Austin, Texas psychologist, echoed Dr. Billings’ concerns. Breeding was instrumental in helping obtain a Texas ban on electroshocking children and adolescents younger than 16. “ECT is an absolute wrong,” said Breeding. “It is a true crime against humanity. It always causes brain damage, it always causes memory loss. It sometimes kills people, and therefore has no place in a ‘therapeutic’ environment. It should be banned.” Fred Shaw, a native of Compton, California, whose work has been honored by the Congressional Black Caucus Foundation, is a former sheriff’s deputy with the Los Angeles County Sheriff’s Department and now a spokesperson for CCHR. He stated: “The fact that in this day and age Americans, including pregnant women and children age five or younger, are still being electroshocked, should be of concern to everyone. It’s important for the public to be aware of the APA’s current push to widen the use of electroshock on children and be a voice to help stop this abuse.” Citizens Commission on Human Rights was established in 1969 by the Church of Scientology and Dr. Thomas Szasz, Professor of Psychiatry and Lifetime Fellow of the APA. CCHR is a 48-year mental health industry watchdog that has obtained over 175 laws that protect individuals against psychiatric abuse. A California State Assembly Recognition of CCHR states: “The contributions that the Citizens Commission on Human Rights International has made to the local, national and international areas on behalf of mental health issues are invaluable and reflect an organization devoted to the highest ideals of mental health services.”


News Article | May 11, 2017
Site: globenewswire.com

CLEARWATER, Fla., May 11, 2017 (GLOBE NEWSWIRE) -- The Citizens Commission on Human Rights (CCHR), a non-profit mental health watchdog co-founded by the Church of Scientology in 1969, working with its Florida chapter, formally requested that Dr. Stephen Ostroff, M.D., Acting Commissioner of the Food and Drug Administration (FDA),  ban the electroshock device. According to the FDA, ECT may cause: prolonged or delayed onset seizures, cardiovascular complications (including heart attacks), breathing complications, confusion, permanent memory loss, brain damage and death.i CCHR noted in its request that despite the dangers an estimated 100,000 Americans receive electroshock annually including children, the elderly and pregnant women. The only state in the country to issue an annual ECT report is Texas where in 2014 six deaths were reported following the use of electroshockii.  CCHR has now filed Freedom of Information Act (FOIA) requests to the remaining U.S. states for the purpose of obtaining statistics on how many children and others are receiving ECT. These FOIA requests revealed that in one state alone, Utah, electroshock was administered 50 times to children and adolescents up to the age of 17 in recent years—including 15 times to those five years old or younger and that Tricare military insurance reported seven children aged 0 to 17 were given ECT in 2016.iii “We have found that visitors to our headquarters in downtown Clearwater are under the assumption that ECT is no longer used or even banned,” said Diane Stein, President CCHR Florida. “This mistaken belief is why our chapter decided to join CCHR International’s petition to ban the ECT device.” In actuality only four U.S. states—Colorado, California, Tennessee and Texas—have banned the use of ECT in children and adolescents despite the fact that the World Health Organization's Resource Book on Mental Health, Human Rights and Legislation, recommended in 2005: "There are no indications for the use of ECT on minors, and hence this should be prohibited through legislation."iv For more information on electroconvulsive therapy or to report harmful side effects from the administration of ECT please fill out this form or contact CCHR at 1-800-869-2247. About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections.  It was L. Ron Hubbard, the founder of Scientology, who brought the terror of psychiatric imprisonment to the notice of the world.  In March 1969, he said, “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed.  All in the name of ‘mental health.’” For more information visit, www.cchrflorida.org. i Neurological Devices Panel, Center for Devices and Radiological Health Medical Devices Advisory Committee, Food and Drug Administration, pp 148-149, 27 Jan. 2011,  https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevicesAdvisoryCommittee/neurologicalDevicesPanel/UCM247594.pdf.%20Accessed%20December%20 "Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses," Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff, 29 Dec. 2015, https://www.fda.gov/downloads/MedicalDevices/%E2%80%A6/UCM478942.pdf ii Jonathon Emord & Associates, Citizens Petition filed with the FDA Commissioner, 14 Aug. 2016; citing Texas Department of State Health Services. Electroconvulsive Therapy (ECT) Reports. FY 2014 ECT Annual Report, page 1. http://www.dshs.texas.gov/mhsa/bhmd/ect/ iii "Evidence for Use of Electroshock on Veterans," 24 July 2015,  https://talkwithtenney.wordpress.com/2015/07/24/evidence-for-use-of-electroshock-on-veterans/ iv Benedetto Saraceno, MD, "WHO Resource Book on Mental Health, Human Rights and Legislation Who 2005," p. 64.


News Article | May 11, 2017
Site: globenewswire.com

CLEARWATER, Fla., May 11, 2017 (GLOBE NEWSWIRE) -- The Citizens Commission on Human Rights (CCHR), a non-profit mental health watchdog co-founded by the Church of Scientology in 1969, working with its Florida chapter, formally requested that Dr. Stephen Ostroff, M.D., Acting Commissioner of the Food and Drug Administration (FDA),  ban the electroshock device. According to the FDA, ECT may cause: prolonged or delayed onset seizures, cardiovascular complications (including heart attacks), breathing complications, confusion, permanent memory loss, brain damage and death.i CCHR noted in its request that despite the dangers an estimated 100,000 Americans receive electroshock annually including children, the elderly and pregnant women. The only state in the country to issue an annual ECT report is Texas where in 2014 six deaths were reported following the use of electroshockii.  CCHR has now filed Freedom of Information Act (FOIA) requests to the remaining U.S. states for the purpose of obtaining statistics on how many children and others are receiving ECT. These FOIA requests revealed that in one state alone, Utah, electroshock was administered 50 times to children and adolescents up to the age of 17 in recent years—including 15 times to those five years old or younger and that Tricare military insurance reported seven children aged 0 to 17 were given ECT in 2016.iii “We have found that visitors to our headquarters in downtown Clearwater are under the assumption that ECT is no longer used or even banned,” said Diane Stein, President CCHR Florida. “This mistaken belief is why our chapter decided to join CCHR International’s petition to ban the ECT device.” In actuality only four U.S. states—Colorado, California, Tennessee and Texas—have banned the use of ECT in children and adolescents despite the fact that the World Health Organization's Resource Book on Mental Health, Human Rights and Legislation, recommended in 2005: "There are no indications for the use of ECT on minors, and hence this should be prohibited through legislation."iv For more information on electroconvulsive therapy or to report harmful side effects from the administration of ECT please fill out this form or contact CCHR at 1-800-869-2247. About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections.  It was L. Ron Hubbard, the founder of Scientology, who brought the terror of psychiatric imprisonment to the notice of the world.  In March 1969, he said, “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed.  All in the name of ‘mental health.’” For more information visit, www.cchrflorida.org. i Neurological Devices Panel, Center for Devices and Radiological Health Medical Devices Advisory Committee, Food and Drug Administration, pp 148-149, 27 Jan. 2011,  https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevicesAdvisoryCommittee/neurologicalDevicesPanel/UCM247594.pdf.%20Accessed%20December%20 "Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses," Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff, 29 Dec. 2015, https://www.fda.gov/downloads/MedicalDevices/%E2%80%A6/UCM478942.pdf ii Jonathon Emord & Associates, Citizens Petition filed with the FDA Commissioner, 14 Aug. 2016; citing Texas Department of State Health Services. Electroconvulsive Therapy (ECT) Reports. FY 2014 ECT Annual Report, page 1. http://www.dshs.texas.gov/mhsa/bhmd/ect/ iii "Evidence for Use of Electroshock on Veterans," 24 July 2015,  https://talkwithtenney.wordpress.com/2015/07/24/evidence-for-use-of-electroshock-on-veterans/ iv Benedetto Saraceno, MD, "WHO Resource Book on Mental Health, Human Rights and Legislation Who 2005," p. 64.


News Article | May 8, 2017
Site: marketersmedia.com

The Citizens Commission on Human Rights (CCHR), a non-profit mental health watchdog dedicated to the eradication of abuses committed under the guise of mental health, joined CCHR International in asking Dr. Stephen Ostroff, M.D., Acting Commissioner of the Food and Drug Administration (FDA), to ban the electroshock device. According to the FDA, ECT may cause: prolonged or delayed onset seizures, cardiovascular complications (including heart attacks), breathing complications, confusion, permanent memory loss, brain damage and death.[1] Yet it is estimated that about 100,000 Americans receive electroshock annually including children, the elderly and pregnant women. The only state in the country to issue an annual ECT report is Texas where in 2014 six deaths were reported following the use of electroshock[2] forcing CCHR to file Freedom of Information Act (FOIA) requests to the remaining U.S. states for the purpose of obtaining statistics on how many children and others are receiving ECT. These FOIA requests revealed that in one state alone, Utah, electroshock was administered 50 times to children and adolescents up to the age of 17 in recent years—including 15 times to those five years old or younger and that Tricare military insurance reported seven children aged 0 to 17 were given ECT in 2016.[3] “We have found that when people tour our Psychiatry: An Industry of Death museum that they are under the assumption that ECT is no longer used or even banned,” said Diane Stein, President CCHR Florida. “This mistaken belief is why our chapter decided to join CCHR International’s petition to ban the ECT device.” In actuality only four U.S. states—Colorado, California, Tennessee and Texas—have banned the use of ECT in children and adolescents despite the fact that the World Health Organization’s Resource Book on Mental Health, Human Rights and Legislation, recommended in 2005: “There are no indications for the use of ECT on minors, and hence this should be prohibited through legislation.”[4] For more information on electroconvulsive therapy or to report harmful side effects from the administration of ECT please fill out this form or contact CCHR at 1-800-869-2247. Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. It was L. Ron Hubbard, the founder of Scientology, who brought the terror of psychiatric imprisonment to the notice of the world. In March 1969, he said, “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed. All in the name of ‘mental health.’” For more information visit, www.cchrflorida.org [1] Neurological Devices Panel, Center for Devices and Radiological Health Medical Devices Advisory Committee, Food and Drug Administration, pp 148-149, 27 Jan. 2011, fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevicesAdvisoryCommittee/neurologicalDevicesPanel/UCM247594.pdf.%20Accessed%20December%20 “Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses,” Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff, 29 Dec. 2015, fda.gov/downloads/MedicalDevices/%E2%80%A6/UCM478942.pdf [2] Jonathon Emord & Associates, Citizens Petition filed with the FDA Commissioner, 14 Aug. 2016; citing Texas Department of State Health Services. Electroconvulsive Therapy (ECT) Reports. FY 2014 ECT Annual Report, page 1. dshs.texas.gov/mhsa/bhmd/ect/ [3] “Evidence for Use of Electroshock on Veterans,” 24 July 2015, talkwithtenney.wordpress.com/2015/07/24/evidence-for-use-of-electroshock-on-veterans/ [4] Benedetto Saraceno, MD, “WHO Resource Book on Mental Health, Human Rights and Legislation Who 2005,” p. 64. For more information, please visit http://www.cchrflorida.org/


News Article | May 11, 2017
Site: globenewswire.com

CLEARWATER, Fla., May 11, 2017 (GLOBE NEWSWIRE) -- The Citizens Commission on Human Rights (CCHR), a non-profit mental health watchdog co-founded by the Church of Scientology in 1969, working with its Florida chapter, formally requested that Dr. Stephen Ostroff, M.D., Acting Commissioner of the Food and Drug Administration (FDA),  ban the electroshock device. According to the FDA, ECT may cause: prolonged or delayed onset seizures, cardiovascular complications (including heart attacks), breathing complications, confusion, permanent memory loss, brain damage and death.i CCHR noted in its request that despite the dangers an estimated 100,000 Americans receive electroshock annually including children, the elderly and pregnant women. The only state in the country to issue an annual ECT report is Texas where in 2014 six deaths were reported following the use of electroshockii.  CCHR has now filed Freedom of Information Act (FOIA) requests to the remaining U.S. states for the purpose of obtaining statistics on how many children and others are receiving ECT. These FOIA requests revealed that in one state alone, Utah, electroshock was administered 50 times to children and adolescents up to the age of 17 in recent years—including 15 times to those five years old or younger and that Tricare military insurance reported seven children aged 0 to 17 were given ECT in 2016.iii “We have found that visitors to our headquarters in downtown Clearwater are under the assumption that ECT is no longer used or even banned,” said Diane Stein, President CCHR Florida. “This mistaken belief is why our chapter decided to join CCHR International’s petition to ban the ECT device.” In actuality only four U.S. states—Colorado, California, Tennessee and Texas—have banned the use of ECT in children and adolescents despite the fact that the World Health Organization's Resource Book on Mental Health, Human Rights and Legislation, recommended in 2005: "There are no indications for the use of ECT on minors, and hence this should be prohibited through legislation."iv For more information on electroconvulsive therapy or to report harmful side effects from the administration of ECT please fill out this form or contact CCHR at 1-800-869-2247. About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections.  It was L. Ron Hubbard, the founder of Scientology, who brought the terror of psychiatric imprisonment to the notice of the world.  In March 1969, he said, “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed.  All in the name of ‘mental health.’” For more information visit, www.cchrflorida.org. i Neurological Devices Panel, Center for Devices and Radiological Health Medical Devices Advisory Committee, Food and Drug Administration, pp 148-149, 27 Jan. 2011,  https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevicesAdvisoryCommittee/neurologicalDevicesPanel/UCM247594.pdf.%20Accessed%20December%20 "Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses," Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff, 29 Dec. 2015, https://www.fda.gov/downloads/MedicalDevices/%E2%80%A6/UCM478942.pdf ii Jonathon Emord & Associates, Citizens Petition filed with the FDA Commissioner, 14 Aug. 2016; citing Texas Department of State Health Services. Electroconvulsive Therapy (ECT) Reports. FY 2014 ECT Annual Report, page 1. http://www.dshs.texas.gov/mhsa/bhmd/ect/ iii "Evidence for Use of Electroshock on Veterans," 24 July 2015,  https://talkwithtenney.wordpress.com/2015/07/24/evidence-for-use-of-electroshock-on-veterans/ iv Benedetto Saraceno, MD, "WHO Resource Book on Mental Health, Human Rights and Legislation Who 2005," p. 64.


News Article | May 11, 2017
Site: globenewswire.com

CLEARWATER, Fla., May 11, 2017 (GLOBE NEWSWIRE) -- The Citizens Commission on Human Rights (CCHR), a non-profit mental health watchdog co-founded by the Church of Scientology in 1969, working with its Florida chapter, formally requested that Dr. Stephen Ostroff, M.D., Acting Commissioner of the Food and Drug Administration (FDA),  ban the electroshock device. According to the FDA, ECT may cause: prolonged or delayed onset seizures, cardiovascular complications (including heart attacks), breathing complications, confusion, permanent memory loss, brain damage and death.i CCHR noted in its request that despite the dangers an estimated 100,000 Americans receive electroshock annually including children, the elderly and pregnant women. The only state in the country to issue an annual ECT report is Texas where in 2014 six deaths were reported following the use of electroshockii.  CCHR has now filed Freedom of Information Act (FOIA) requests to the remaining U.S. states for the purpose of obtaining statistics on how many children and others are receiving ECT. These FOIA requests revealed that in one state alone, Utah, electroshock was administered 50 times to children and adolescents up to the age of 17 in recent years—including 15 times to those five years old or younger and that Tricare military insurance reported seven children aged 0 to 17 were given ECT in 2016.iii “We have found that visitors to our headquarters in downtown Clearwater are under the assumption that ECT is no longer used or even banned,” said Diane Stein, President CCHR Florida. “This mistaken belief is why our chapter decided to join CCHR International’s petition to ban the ECT device.” In actuality only four U.S. states—Colorado, California, Tennessee and Texas—have banned the use of ECT in children and adolescents despite the fact that the World Health Organization's Resource Book on Mental Health, Human Rights and Legislation, recommended in 2005: "There are no indications for the use of ECT on minors, and hence this should be prohibited through legislation."iv For more information on electroconvulsive therapy or to report harmful side effects from the administration of ECT please fill out this form or contact CCHR at 1-800-869-2247. About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections.  It was L. Ron Hubbard, the founder of Scientology, who brought the terror of psychiatric imprisonment to the notice of the world.  In March 1969, he said, “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed.  All in the name of ‘mental health.’” For more information visit, www.cchrflorida.org. i Neurological Devices Panel, Center for Devices and Radiological Health Medical Devices Advisory Committee, Food and Drug Administration, pp 148-149, 27 Jan. 2011,  https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevicesAdvisoryCommittee/neurologicalDevicesPanel/UCM247594.pdf.%20Accessed%20December%20 "Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses," Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff, 29 Dec. 2015, https://www.fda.gov/downloads/MedicalDevices/%E2%80%A6/UCM478942.pdf ii Jonathon Emord & Associates, Citizens Petition filed with the FDA Commissioner, 14 Aug. 2016; citing Texas Department of State Health Services. Electroconvulsive Therapy (ECT) Reports. FY 2014 ECT Annual Report, page 1. http://www.dshs.texas.gov/mhsa/bhmd/ect/ iii "Evidence for Use of Electroshock on Veterans," 24 July 2015,  https://talkwithtenney.wordpress.com/2015/07/24/evidence-for-use-of-electroshock-on-veterans/ iv Benedetto Saraceno, MD, "WHO Resource Book on Mental Health, Human Rights and Legislation Who 2005," p. 64.


News Article | May 11, 2017
Site: globenewswire.com

Guernsey, 11 May 2017 - Eurocastle Investment Limited ("Eurocastle" or the "Company") today announces that it will release its financial results for the first quarter ended 31 March 2017 on Thursday, 18 May 2017 before the market opens. In addition, management will host an earnings conference call at 2:00 P.M. London time (9:00 A.M. New York time) later that day. All interested parties are welcome to participate on the live call. You can access the conference call by dialing first +1-800-215-5243 (from within the U.S.) or +1-330-863-8154 (from outside of the U.S.) ten minutes prior to the scheduled start of the call; please reference "Eurocastle First Quarter 2017 Earnings Call or conference ID number 21936653" A webcast of the conference call will be available to the public on a listen-only basis at www.eurocastleinv.com. Please allow extra time prior to the call to visit the site and download the necessary software required to listen to the internet broadcast. A replay of the webcast will be available for three months following the call. For those who are not available to listen to the live call, a replay will be available until 11:59 P.M. New York time on Thursday, 01 June 2017 by dialing +1-855-859-2056 (from within the U.S.) or +1-404- 537-3406 (from outside of the U.S.); please reference access code "21936653" Eurocastle Investment Limited is a publicly traded closed-ended investment company that focuses on investing in performing and non-performing loans and other real estate related assets primarily in Italy. The Company is Euro denominated and is listed on Euronext Amsterdam under the symbol "ECT". Eurocastle is managed by an affiliate of Fortress Investment Group LLC, a leading global investment manager. For more information regarding Eurocastle Investment Limited and to be added to our email distribution list, please visit www.eurocastleinv.com.


Erected in the heart of the city's Downtown Eastside, the hard hitting exhibit covers the history of psychiatry from its early barbaric practices to the social mind bending “treatments” and abusive practices of today which include electroconvulsive therapy (ECT), placing brain stimulating wires in the brain, use of restraints and over drugging from children to the elderly. As part of the Of great concern is the treatment of children - in a recent Canadian study, it stated that one in 20 kids is diagnosed with Attention Deficit Disorder and one in 10 is prescribed anti-psychotic drugs as well as anti-depressants on top of the stimulant drugs for ADHD. These are given to children as young as 6 years old. The side effects include sleep terror, emotional disorder, moaning, convulsion, weight loss, chest pain, muscle twitching, intentional self-injury, depression, staring and fecal incontinence. Antipsychotics are also increasingly being used “off label” for children with attention-deficit-hyperactivity disorder, “conduct” disorders, aggression and other behavioural problems. The drugs can increase suicidal thinking in young people, and studies suggest they are little better than placebo in mild to moderate cases. “Children are the perfect candidates for the psychiatric industry”, said Brian Beaumont, President for CCHR BC. “Once hooked on these drugs, it is painful and extremely difficult to get off, and they will need treatment and be medicated throughout their lives,” added Beaumont. “We hope to raise awareness with this exhibit so parents and medical professionals can make better choices regarding the use of harmful drugs and treatment in particular with children.” The Citizens Commission on Human Rights (CCHR) is a nonprofit mental health watchdog, responsible for helping to enact more than 150 laws protecting individuals from abusive or coercive practices. CCHR has long fought to restore basic inalienable human rights to the field of mental health, including, but not limited to, full informed consent regarding the medical legitimacy of psychiatric diagnosis, the risks of psychiatric treatments, the right to all available medical alternatives, and the right to refuse any treatment considered harmful. The traveling exhibit stayed up at 168 East Pender until May 7th.


News Article | May 11, 2017
Site: www.marketwired.com

Enbridge Income Fund Holdings Inc. (TSX:ENF) (ENF or the Company) announced first quarter earnings of $67 million, or $0.54 per common share. The Company holds a 66.9 percent ordinary trust unit (Fund Unit) interest in Enbridge Income Fund (the Fund) and an approximate 19.2 percent overall economic interest in the Fund Group. The Fund Group is comprised of the Fund, Enbridge Commercial Trust (ECT), Enbridge Income Partners LP (EIPLP) and the subsidiaries and investees of EIPLP. EIPLP holds the operating entities of the Fund Group. Fund Group ACFFO was $422 million for the three months ended March 31, 2017, with cash distributions paid of $403 million, resulting in a payout ratio of 95 percent of ACFFO. As anticipated, first quarter ACFFO was down versus the comparable period in 2016 due to a lower Canadian Mainline International Joint Tariff (IJT) Residual Benchmark Toll, though throughput in the quarter continued to be very strong. On April 1, 2017, the Canadian Mainline IJT Residual Benchmark Toll increased by US$0.15 per barrel and the higher toll is expected to be in place for the remainder of 2017, providing an uplift to ACFFO for the balance of the year. Strong performance from Alliance Pipeline's new services framework driven by high demand for seasonal firm service also contributed positively to ACFFO performance in the first quarter of 2017. "We are pleased with the results for the quarter, which set us up well to deliver on the Fund Group's 2017 ACFFO guidance range," said Company President Perry Schuldhaus. "Demand for the mainline continues to be strong, with record volumes of 2.6 million barrels per day ex-Gretna in the first quarter. We expect the balance of the year to benefit from continued strong demand for capacity and a higher mainline toll which took effect on April 1, 2017. This is expected to drive higher earnings and cash flow and result in a cash payout ratio for the full year well below our longer term target payout ratio of 90 percent of ACFFO." On May 1, 2017, the Norlite Pipeline project was placed into commercial service, on time and on budget. The project will initially carry up to 218 thousands of barrels per day (kbpd) of diluent from Edmonton, Alberta to producers in Northern Alberta, with the potential to be further expanded to approximately 465 kbpd of capacity with the addition of pump stations. The project is a joint venture with Keyera Corporation (Keyera), which owns a 30 percent non-operating interest in the project. The total project cost was $1.3 billion, with Keyera contributing 30 percent of the project's capital. "Thus far in 2017, the Fund Group has placed $2.2 billion of capital into service on budget and on schedule, and we expect to place another $1.5 billion into service before year end," said Mr. Schuldhaus. "These projects will generate highly reliable and predictable earnings and cash flow, and further strengthen our unparalleled portfolio of low-risk energy infrastructure. Utilization of our assets continues to be strong and, with additional organic growth to come, we remain very well positioned to deliver 10 percent annual dividend increases through 2019." On April 18, 2017, Enbridge and the Company closed on a $0.6 billion secondary offering of ENF common shares (the Offering). The Offering was consistent with Enbridge's stated goal to gradually reduce its economic interest in the Fund Group to approximately 80 percent by 2019. The Offering was well received by the market and is expected to improve the trading liquidity of ENF shares. The Company previously announced a 10 percent increase in its monthly dividend to $0.1711 per common share, commencing with the dividend payable in respect of January 2017. On May 9, 2017, the Company's Board of Directors also declared a monthly cash dividend of $0.1711 per common share to be paid on June 15, 2017 to shareholders of record at the close of business on May 31, 2017. These dividends are designated eligible dividends for Canadian tax purposes which qualify for the enhanced dividend tax credit. Eligible shareholders may elect to participate in the Company's Dividend Reinvestment and Share Purchase Plan (DRIP), where they may automatically reinvest their dividends in additional shares at a 2 percent discount to the share price without brokerage fees. Details of the DRIP are available on the Company's website. Shareholders who wish to participate in the DRIP should contact their investment dealer for further information and to enroll. This news release contains references to adjusted EBIT and ACFFO. Adjusted EBIT represents EIPLP EBIT, adjusted for unusual, non-recurring or non-operating factors on both a consolidated and segmented basis. These factors, referred to as adjusting items, are reconciled and discussed in the financial results sections of this news release. Fund Group ACFFO consists of adjusted EBIT further adjusted for non-cash items, representing cash flow from the Fund Group's underlying businesses, less deductions for maintenance capital expenditures, interest expense, and applicable taxes and further adjusted for unusual, non-recurring or non-operating factors not indicative of the underlying or sustainable cash flows of the business. ACFFO is important to unitholders as the Fund Group's objective is to provide a predictable flow of distributions to unitholders. ACFFO represents the Fund Group's cash available to fund distributions to unitholders, as well as for debt repayments and reserves. Management believes the presentation of adjusted EBIT and ACFFO are useful to investors and unitholders as they provide increased transparency and insight into the performance of the Company and the Fund Group. Management uses adjusted EBIT and ACFFO to set targets, including the distribution payout target, and to assess the performance of the Company and the Fund Group. Adjusted EBIT and ACFFO are not measures that have standardized meanings prescribed by generally accepted accounting principles in the United States of America (U.S. GAAP) and are not U.S. GAAP measures. Therefore, these measures may not be comparable with similar measures presented by other issuers. Please see the tables in the First Quarter 2017 Performance Overview section which summarize the reconciliations of the GAAP and non-GAAP measures. For more information on the operating results of the Company, the Fund and EIPLP, please see the respective Management's Discussion and Analysis on the Company's website at http://www.enbridgeincomefund.com/Find-Shareholder-Information/Reports-and-Filings/English.aspx. The documents are also filed on SEDAR under Enbridge Income Fund Holding Inc.'s profile for the Company and under Enbridge Income Fund's profile for the Fund and EIPLP. EIPLP's EBIT for the first quarter of 2017 was $619 million compared to $1,097 million for the same quarter of 2016. The comparability of EIPLP's earnings was impacted by a number of unusual, non-recurring or non-operating factors, the most significant of which relates to changes in unrealized derivative fair value gains and losses. Excluding the impact of unusual, non-recurring or non-operating factors, EIPLP's EBIT decreased for the first quarter of 2017, primarily as a result of lower contributions from the Liquids Pipelines segment, which was partially offset by stronger contributions from the Gas Pipelines segment. EIPLP adjusted EBIT for the first quarter of 2017 was $464 million compared to $553 million over the same period of 2016, reflecting a lower quarter-over-quarter average Canadian Mainline IJT Residual Benchmark Toll, which was US$1.47 as compared to US$1.63 in the first quarter of 2016. Effective April 1, 2017, the toll increased to US$1.62. Also contributing to lower adjusted EBIT was a lower foreign exchange hedge rate used to record Canadian Mainline revenues. The IJT Benchmark Toll and its components are set in United States dollars and the majority of EIPLP's foreign exchange risk on Canadian Mainline revenues is hedged. The effective hedge rate for the translation of Canadian Mainline United States dollar transactional revenues for the first quarter of 2017 was $1.04 compared with $1.11 for the corresponding 2016 period. The above noted negative impacts on Canadian Mainline adjusted EBIT were partially offset by higher throughput on the mainline system driven by strong oil sands production and downstream demand in the first quarter of 2017. Partially offsetting the quarter-over-quarter decrease were stronger contributions from the Gas Pipelines segment, driven by increased earnings at Alliance Pipeline primarily due to higher revenues resulting from strong demand for seasonal firm service. Fund Group ACFFO underpins the Fund Group's ability to pay distributions to holders of Fund Units, including the Company. The Fund Group's ACFFO decreased to $422 million for the three months ended March 31, 2017 from $515 million in the comparable period of 2016. Similar to adjusted EBIT, the decrease in ACFFO was driven by weaker contributions from EIPLP's Liquids Pipelines segment due to a lower quarter-over-quarter average Canadian Mainline IJT Residual Benchmark Toll and a lower foreign exchange hedge rate used to record Canadian Mainline revenues, discussed above in Adjusted EBIT. This decrease has resulted in a higher Fund Group payout ratio of 95% in the first quarter of 2017 compared to 75% in the corresponding period of 2016; however, following the increase in Canadian Mainline IJT Residual Benchmark Toll from US$1.47 to US$1.62 effective April 1, 2017, the Fund Group payout ratio is anticipated to decrease well below 90% for the balance of the year. The Company's distribution income represents substantially all of the Company's earnings and cash flows, and is derived from the Fund Group distributions paid to the Company. For the three months ended March 31, 2017, distribution income was $67 million, an increase of approximately 29 percent from the comparable period of 2016, as a result of the Company using proceeds from its April 2016 equity offering and proceeds from the Company's DRIP to invest in additional Fund Units. The following table summarizes the dividend rate and total dividends declared by the Company for the three months ended March 31, 2017 and 2016. On April 18, 2017, Enbridge completed the secondary offering of 17,347,750 ENF common shares at a price of $33.15 per share to the public for gross proceeds to Enbridge of approximately $0.6 billion (the Secondary Offering). Immediately prior to the closing of the Secondary Offering, Enbridge exchanged 21,657,617 Fund Units for an equivalent amount of ENF common shares. In order to maintain its 19.9 percent interest in the Company, Enbridge retained 4,309,867 of the common shares issued pursuant to such exchange and sold the remaining balance under the Secondary Offering. The Company did not receive any proceeds from the Secondary Offering and Enbridge paid all expenses and fees associated with the Secondary Offering. Upon closing of the transaction, Enbridge's economic interest in the Fund Group and the Company decreased from 86.9 percent to 84.6 percent and the Company's economic interest in the Fund Group increased from 16.4 percent to 19.2 percent. The Company will hold a joint conference call with Enbridge, Enbridge Energy Partners, L.P. and Spectra Energy Partners, LP on Thursday, May 11, 2017 at 9 a.m. Eastern Time (7 a.m. Mountain Time) to discuss the first quarter 2017 results. Analysts, members of the media and other interested parties can access the call toll-free at 1-866-215-5508 or outside North America at 1-514-841-2157 using the access code of 44798051#. The call will be audio webcast live at http://edge.media-server.com/m/p/9gxn6d2m. A webcast replay and podcast will be available approximately two hours after the conclusion of the event and a transcript will be posted to the website within approximately 24 hours. An audio replay will be available for seven days after the call toll-free at 1-888-843-7419 or outside North America at 1-630-652-3042 using the replay passcode 44798051#. The conference call will begin with presentations by Enbridge's President and Chief Executive Officer and the Chief Financial Officer, followed by a question and answer period with Enbridge and ENF management for investment analysts. Forward-looking information, or forward-looking statements, have been included in this news release to provide information about the Company and its investee, the Fund, and the Fund's direct and indirect investments and joint ventures (collectively, the Fund Group), including management's assessment of future plans and operations of the Company and the Fund Group. This information may not be appropriate for other purposes. Forward-looking statements are typically identified by words such as "anticipate", "expect", "project", "estimate", "forecast", "plan", "intend", "target", "believe", "likely" and similar words suggesting future outcomes or statements regarding an outlook. Forward-looking information or statements included or incorporated by reference in this document include, but are not limited to, statements with respect to the following: mainline system throughput; expected or target ACFFO; cash flows; equity capital requirements; in-service dates of projects; safety and reliability of pipeline systems; regulatory approvals; impact of the hedging program; shareholder returns; future dividends and distributions by the Fund; and dividend increases. Although the Company and the Fund Group believe these forward-looking statements are reasonable based on the information available on the date such statements are made and processes used to prepare the information, such statements are not guarantees of future performance and readers are cautioned against placing undue reliance on forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements. Material assumptions include assumptions about the following: supply of and demand for crude oil, natural gas, natural gas liquids (NGL) and renewable energy; prices of crude oil, natural gas, NGL and renewable energy; exchange rates; completion of growth projects; inflation; interest rates; availability and price of labour and construction materials; operational reliability; customer and regulatory approvals; maintenance of support and regulatory approvals for the Fund Group's projects; anticipated in-service dates; weather; the impact of the dividend policy on the Company's or the Fund Group's future cash flows; capital project funding; the Fund Group's credit ratings; earnings before interest and taxes (EBIT) or adjusted EBIT; earnings/(loss) or adjusted earnings/(loss); earnings/(loss) per share; future cash flows and future ACFFO; and dividends or distributions. Assumptions regarding the expected supply of and demand for crude oil, natural gas, NGL and renewable energy, and the prices of these commodities, are material to and underlie all forward-looking statements. These factors are relevant to all forward-looking statements as they may impact current and future levels of demand for the Fund Group's services. Similarly, exchange rates, inflation and interest rates impact the economies and business environments in which the Company and the Fund Group operate and may impact levels of demand for the Fund Group's services and cost of inputs, and are therefore inherent in all forward-looking statements. Due to the interdependencies and correlation of these macroeconomic factors, the impact of any one assumption on a forward-looking statement cannot be determined with certainty, particularly with respect to earnings/(loss), adjusted EBIT, ACFFO and associated per share amounts or dividends or distributions. The most relevant assumptions associated with forward-looking statements on projects under construction, including completion dates and capital expenditures include the following: availability and price of labour and construction materials; effects of inflation and foreign exchange rates on labour and material costs; effects of interest rates on borrowing costs; and the impact of weather and customer, government and regulatory approvals on construction and in-service schedules and cost recovery regimes. The Company's and the Fund Group's forward-looking statements are subject to risks and uncertainties pertaining to future dividends, ACFFO guidance, operating performance, regulatory parameters, project approval and support, weather, economic and competitive conditions, public opinion, changes in tax laws and tax rates, exchange rates, interest rates, commodity prices, political decisions and supply of and demand for commodities, including but not limited to those risks and uncertainties discussed in this news release and in the Company's and the Fund Group's other filings with Canadian securities regulators. The impact of any one risk, uncertainty or factor on a particular forward-looking statement is not determinable with certainty as these are interdependent and the Company's or the Fund Group's future course of action depends on management's assessment of all information available at the relevant time. Except to the extent required by applicable law, the Company and the Fund Group assume no obligation to publicly update or revise any forward-looking statements made in this news release or otherwise, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements, whether written or oral, attributable to the Company or the Fund Group or persons acting on the Company's or the Fund Group's behalf, are expressly qualified in their entirety by these cautionary statements. Enbridge Income Fund Holdings Inc. is a publicly traded corporation. The Company, through its investment in Enbridge Income Fund indirectly holds high quality, low-risk energy infrastructure assets. The Fund's assets consist of a portfolio of Canadian liquids transportation and storage businesses, including the Canadian Mainline, the Regional Oil Sands System, the Canadian segment of the Southern Lights Pipeline, Class A units entitling the holder to receive defined cash flows from the United States segment of the Southern Lights Pipeline, a 50 percent interest in the Alliance Pipeline, which transports natural gas from Canada to the U.S., and interests in more than 1,400 megawatts of renewable and alternative power generation assets. Information about Enbridge Income Fund Holdings Inc. is available on the Company's website at www.enbridgeincomefund.com. None of the information contained in, or connected to, the Company's website is incorporated in or otherwise forms part of this news release.

Loading ECT GmbH collaborators
Loading ECT GmbH collaborators